FDA gives stamp of approval for kidney cancer drug
Filed under: Drug, Kidney Cancer, Research, Daily news
New cancer drug Torisol was approved on Wednesday by the FDA for use with renal cell carcinoma, an advanced form of kidney cancer.
Torisol, also known as temsirolimus, is an enzyme inhibitor made by Wyeth Pharmaceuticals and has shown promise for prolonging patient survival. It’s the third kidney cancer drug approved in the past 18 months — the other two are Nexavar, intended to delay disease progression, and Sutent, for tumor size reduction.
Many kidney cancer patients are cured by surgery. About 35 percent of patients, however, experience a recurrence or a spread of the disease. Until just recently, there were no effective drugs to control these issues. Now there are several — and Torisol is the one showing modest improvement in survival for patients with the most advanced tumors. Further study will indicate whether or not the drug is useful for patients with less extensive metastatic disease.
Read | Permalink | Email this | Linking Blogs | Comments
Original post by Jacki Donaldson
No comments yet. Be the first.
Leave a reply
FDA gives stamp of approval for kidney cancer drug
Filed under: Drug, Kidney Cancer, Research, Daily news
New cancer drug Torisol was approved on Wednesday by the FDA for use with renal cell carcinoma, an advanced form of kidney cancer.
Torisol, also known as temsirolimus, is an enzyme inhibitor made by Wyeth Pharmaceuticals and has shown promise for prolonging patient survival. It’s the third kidney cancer drug approved in the past 18 months — the other two are Nexavar, intended to delay disease progression, and Sutent, for tumor size reduction.
Many kidney cancer patients are cured by surgery. About 35 percent of patients, however, experience a recurrence or a spread of the disease. Until just recently, there were no effective drugs to control these issues. Now there are several — and Torisol is the one showing modest improvement in survival for patients with the most advanced tumors. Further study will indicate whether or not the drug is useful for patients with less extensive metastatic disease.
Read | Permalink | Email this | Linking Blogs | Comments
Original post by Jacki Donaldson
No comments yet. Be the first.
Leave a reply